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XBP1 is a key regulator of the unfolded protein
response (UPR), which is involved in a wide range
of physiological and pathological processes. XBP1
ablation in liver causes profound hypolipidemia in
mice, highlighting its critical role in lipid metabolism.
XBP1 deficiency triggers feedback activation of
its upstream enzyme IRE1a, instigating regulated
IRE1-dependent decay (RIDD) of cytosolic mRNAs.
Here, we identify RIDD as a crucial control mecha-
nism of lipid homeostasis. Suppression of RIDD
by RNA interference or genetic ablation of IRE1a
reversed hypolipidemia in XBP1-deficient mice.
Comprehensive microarray analysis of XBP1 and/or
IRE1a-deficient liver identified genes involved in
lipogenesis and lipoprotein metabolism as RIDD
substrates, which might contribute to the suppres-
sion of plasma lipid levels by activated IRE1a.
Ablation of XBP1 ameliorated hepatosteatosis, liver
damage, and hypercholesterolemia in dyslipidemic
animal models, suggesting that direct targeting of
either IRE1a or XBP1 might be a feasible strategy
to treat dyslipidemias.
INTRODUCTION
The unfolded protein response (UPR) was originally identified
as a signaling system that promotes the transcription of endo-
plasmic reticulum (ER) chaperone genes in response to stresses
that burden the ER with increased client proteins for folding (Ron
and Walter, 2007; Schro¨der and Kaufman, 2005). In mammals,CellUPR is initiated by three families of unique ER transmembrane
proteins, PERK, IRE1 (IRE1a and IRE1b), and ATF6 (ATF6a
and ATF6b). IRE1 is evolutionarily well conserved in all eukary-
otes from unicellular organisms to mammals, while the other
UPR branches are present only in higher eukaryotes (Cox
et al., 1993; Mori et al., 1993; Ron and Walter, 2007; Wang
et al., 1998).
XBP1 is the only known transcription factor downstream of
IRE1a that is activated through an unconventional mRNA
splicing reaction. XBP1 activates the transcription of a variety
of genes involved in protein secretory pathways (Acosta-Alvear
et al., 2007; Lee et al., 2003; Shaffer et al., 2004). In line with
this, IRE1a and XBP1 are required for the development,
the survival, and the protein secretory function of some profes-
sional secretory cells (Huh et al., 2010; Iwawaki et al., 2010;
Kaser et al., 2008; Lee et al., 2005; Reimold et al., 2001; Zhang
et al., 2005).
In addition to activating XBP1, IRE1a can also activate Jun
N-terminal kinase (JNK) (Urano et al., 2000) and induce the
degradation of certain mRNAs, a process known as regulated
IRE1-dependent decay (RIDD) (Han et al., 2009; Hollien et al.,
2009; Lee et al., 2011; Lipson et al., 2008; Oikawa et al.,
2010). The physiological significance of RIDD was first explored
in insect cells, where it was postulated to be a mechanism to
reduce ER stress by limiting the entry of cargo proteins to the
ER, given the preferential degradation of mRNAs encoding
secretory proteins by RIDD (Hollien and Weissman, 2006).
Interestingly, in mammalian cells, IRE1a appears to cleave
mRNAs encoding not only secretory cargo proteins, but also
ER resident proteins that serve in protein folding and secretory
pathways. This has led to the hypothesis that IRE1a might
promote apoptosis under severe ER stress conditions by
diminishing ER capacity to handle stress (Han et al., 2009).
The in vivo functions of RIDD are only beginning to be ex-
plored. We and others have demonstrated that IRE1a degradesMetabolism 16, 487–499, October 3, 2012 ª2012 Elsevier Inc. 487
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Role of IRE1a in Lipid Metabolisminsulin mRNA as well as proinsulin-processing enzyme mRNAs,
uncovering an important function of RIDD in insulin secre-
tion from b cells (Han et al., 2009; Lee et al., 2011; Lipson
et al., 2008). IRE1b, which is specifically expressed in the
epithelial cells of the gastrointestinal tract, was shown to
degrade the mRNA encoding microsomal triglyceride transfer
protein, and hence to suppress chylomicron production (Iqbal
et al., 2008).
We previously reported that XBP1 ablation in the liver pro-
foundly decreased plasma triglyceride (TG) and cholesterol
levels in mice, revealing an important role for this factor in
hepatic lipid metabolism (Lee et al., 2008). Contrary to our spec-
ulation that XBP1 deficiency might induce ER stress in hepato-
cytes, leading to decreased very-low-density lipoprotein
(VLDL) secretion, XBP1-deficient hepatocytes did not exhibit
morphological signs of ER dysfunction, defects in apoB100
secretion, TG accumulation, increased apoptosis, or activation
of XBP1-independent UPR markers, arguing against the contri-
bution of ER stress to the hypolipidemic phenotype of themutant
mice. Instead, we found that the expression of key lipogenic
enzyme genes was reduced in XBP1-deficient liver. Some but
not all of these genes were directly induced by XBP1s overex-
pression, indicating that XBP1 acts as a prolipogenic transcrip-
tion factor.
While XBP1 plays an important role in hepatic lipid metabo-
lism, several studies have also reported UPR activation in alco-
holic and nonalcoholic fatty liver diseases (Ji and Kaplowitz,
2003; Ozcan et al., 2004; Puri et al., 2008), suggesting the pres-
ence of ER stress in these metabolic abnormalities (Hotamisligil,
2008). Although it remains unclear how lipids activate the UPR
(or cause ER stress), the idea that ER stress might contribute
to the pathogenesis of dyslipidemic metabolic diseases remains
an interesting one.
Although XBP1 ablation did not activate PERK or ATF6, it
strongly activated its upstream enzyme, IRE1a, indicating
feedback regulation of IRE1a activity by the abundance of its
substrate XBP1s (Lee et al., 2008). Hyperactivated IRE1a
possesses ribonuclease activity to induce the degradation of
certain mRNAs by RIDD, such as those encoding cytochrome
P450 enzymes that carry out detoxification of xenobiotics
(Hur et al., 2012). Here, we demonstrate that RIDD also
plays an important role in hepatic lipid metabolism. Suppres-
sion of RIDD by IRE1a siRNA markedly restored plasma TG
and cholesterol levels in XBP1 knockout mice, along with
the induction of lipid metabolism genes. Gene expression
profiling revealed a group of lipid metabolism genes regulated
by RIDD, which included Angptl3 and the carboxylesterase 1
(Ces1) gene family, whose suppression decreases plasma
lipids (Koishi et al., 2002; Musunuru et al., 2010; Quiroga and
Lehner, 2011; Romeo et al., 2009). Contrary to the notion
that XBP1 mitigates ER stress induced by fat accumula-
tion, XBP1 ablation ameliorated hepatic steatosis in ob/ob
mice and liver damage induced by long-term high-fat-diet
feeding, consistent with the distinct role of IRE1a/XBP1 in lipid
metabolism. We also demonstrate that siRNA-mediated
silencing of XBP1 mRNA in the liver effectively lowers
plasma lipids in mice, providing ‘‘proof of principle’’ that tar-
geting XBP1 may be a viable approach to the treatment of
dyslipidemias.488 Cell Metabolism 16, 487–499, October 3, 2012 ª2012 Elsevier InRESULTS
Partial Restoration of Plasma Lipid Levels
by Suppression of IRE1a in Xbp1D Mice
We previously demonstrated that an inducible deletion of Xbp1
in the liver decreased plasma cholesterol and TG levels in
mice, while preserving normal hepatic lipid contents and com-
position (Lee et al., 2008). As XBP1 deficiency also resulted in
constitutive activation of IRE1a, which could potentially mediate
XBP1-independent functions, we sought to determine the
contribution of hyperactivated IRE1a to the hypolipidemic
phenotype of XBP1-deficient mice. Xbp1f/f;Alb-cre (Xbp1LKO)
mice which expressed Cre recombinase in postnatal liver
under the control of the mouse albumin enhancer/promoter
displayed markedly lower plasma TG and cholesterol levels
compared to their Xbp1f/f littermate controls (Figures 1A and
1B). Plasma lipid levels were not altered in heterozygous
Xbp1f/+;Alb-cre mice. Similar results were obtained in females
(see Figures S1A and S1B online). Lipogenic enzyme genes
such as Dgat2, Acacb, and Scd1 were suppressed in the liver
of Xbp1LKO mice (Figure 1C), similar to what we observed in
the inducible XBP1-deficient mouse strain (Lee et al., 2008).
To investigate the function of hyperactivated IRE1a in hepatic
lipid metabolism, we silenced IRE1a expression in the liver of
Xbp1LKO mice using siRNA, as described elsewhere (Hur et al.,
2012). IRE1a siRNA markedly increased plasma TG and choles-
terol levels in Xbp1LKO mice, indicating that hyperactivated
IRE1a contributed to the reduction of plasma lipids in the
setting of XBP1 deficiency (Figures 1D and 1E). Injection of
IRE1a siRNA into Xbp1LKO mice significantly increased Dgat2
and Acacb mRNAs, which play crucial roles in fatty acid metab-
olism and were suppressed in Xbp1-deficient liver (Figure 1F).
Pcsk9, which promotes the degradation of LDL receptor (Horton
et al., 2007), was also induced by IRE1a siRNA, suggesting
that these mRNAs are degraded after cleavage by hyperacti-
vated IRE1a in XBP1-deficient liver. In contrast, WT C57BL/6
mice injected with IRE1a siRNA exhibited slightly lower plasma
TG and cholesterol levels compared with the control siRNA-
injected group (Figure S1C), consistent with the phenotype of
genetically IRE1a-ablated mice as described below.
Modest Hypolipidemia in IRE1a-Deficient Mice
Since IRE1a silencing restored the plasma lipid concentrations
to near-normal levels in Xbp1-deficient mice, we asked whether
XBP1 regulates plasma lipid levels solely by modulating IRE1a
activity or has a separate function in hepatic lipid metabolism.
We sought to determine the relative contributions of XBP1
deficiency and IRE1a hyperactivation to the dyslipidemia
phenotype of Xbp1LKO mice. It is notable that IRE1a siRNA
only partially restored plasma lipid levels in Xbp1LKO mice (Fig-
ure 1), suggesting that XBP1 itself may also play a role in lipid
metabolism independent of RIDD. XBP1-deficient mice with
normal IRE1a activity would reveal the direct role of XBP1 in
hepatic lipid metabolism, but this was not a feasible approach.
As an alternative, we examined IRE1a-deficient mice that do
not produce the active XBP1s protein. IRE1a-deficient mice
were generated by crossing Ern1flox mice with Mx1-cre mice,
which allowed inducible deletion of IRE1a in the liver upon
poly(I:C) administration. Without poly(I:C) administration, plasmac.
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Figure 1. Partial Restoration of Plasma
Lipid Levels by IRE1a Silencing in XBP1-
Deficient Mice
(A and B) (A) Plasma TG and (B) cholesterol levels
of male mice with the indicated genotypes
measured at fed state.
(C) Expression of lipid metabolism genes in male
Xbp1LKO mice determined by qRT-PCR. n = 8–9
per group.
(D and E) (D) Xbp1LKO mice were i.v. injected with
siRNAs targeting luciferase or IRE1a mRNA.
Plasma TG and (E) cholesterol levels were
measured at indicated time points. n = 8–9 per
group.
(F) Xbp1LKO mice were sacrificed 2 or 8 days
after siRNA or PBS injection. Hepatic mRNA levels
were measured by qRT-PCR. Values represent
mean ± SEM. n = 2 (PBS), or 3–6 (siRNA). *p < 0.05,
**p < 0.01, ***p < 0.001.
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Role of IRE1a in Lipid MetabolismTG and cholesterol levels were comparable between Ern1f/f and
Ern1f/f;Mx1-cre mice (Figures 2A and 2B). Notably, poly(I:C)
administration significantly decreased both plasma TG and
cholesterol levels in Ern1f/f;Mx1-cre mice (Ire1D), but not in the
control Ern1flox/flox mice, indicating that XBP1s is required to
maintain normal plasma lipid levels. Moreover, IRE1a and
XBP1 double-deficient mice exhibited modestly decreased
plasma TG and cholesterol levels compared with WT littermates
(Figures 2C and 2D), consistent with the results from IRE1a
siRNA-injected Xbp1LKO mice (Figures 1C and 1D). XBP1 and/or
IRE1a mRNA levels were decreased by >90% in Ire1D/Xbp1DCell Metabolism 16, 487–499and Ire1D mice compared to controls
(Figure S2). These data suggest that the
lack of XBP1s and the hyperactivation of
IRE1a both contribute to the dramatic
decrease of plasma lipids observed in
the setting of XBP1 deficiency and do
so via separate mechanisms.
Identification of Direct XBP1
Targets and RIDD Substrates
in Liver
We next sought to identify lipid metabo-
lism genes that are directly regulated by
XBP1 and those regulated by RIDD.
We reasoned that genes downregulated
in XBP1-deficient liver would fall into
two groups: RIDD substrates and direct
XBP1 targets. To identify RIDD substrate
mRNAs and direct XBP1 targets in the
liver, we performed a comprehensive
comparative microarray analysis of three
groups of RNA samples: WT and XBP1-
deficient mice, WT and IRE1a-deficient
mice untreated or injected with tunicamy-
cin, and XBP1-deficient mice injected
with luciferase or IRE1a siRNA. We iden-
tified 237 geneswhosemRNA levels were
significantly lower in XBP1 knockoutmicethan in theWT littermate controls (Figure 3 and Table S1). Among
these XBP1-dependent genes, 64 genes were also downregu-
lated in IRE1a-deficient liver, hence representing likely direct
XBP1 target genes. A majority of these genes were induced by
tunicamycin treatment in WT, but not in Ire1D mice, indicating
that XBP1s directly activates their transcription (Figures 3A
and 3B). Gene ontology analysis revealed that genes involved
in ‘‘Protein processing in endoplasmic reticulum (KEGG
mmu04141)’’ were highly enriched in this group, consistent
with the critical function of XBP1 in protein secretory pathways
(Lee et al., 2003; Shaffer et al., 2004). Notably, the expression, October 3, 2012 ª2012 Elsevier Inc. 489
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Figure 2. Plasma Lipid Levels in IRE1a, and IRE1a/XBP1 Double
Deficient Mice
(A and B) (A) Plasma TG and (B) cholesterol levels were measured before and
3 weeks after poly(I:C) injection of male Ern1f/f and Ern1f/f;Mx1-cre mice.
Bloods were drawn at fed state.
(C and D) Plasma lipid levels of Ern1f/f;Xbp1f/f and Ern1f/f;Xbp1f/f;Mx1-cre mice
before and 3 weeks after poly(I:C) injection. Values represent mean ± SEM.
**p < 0.01, ***p < 0.001.
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Role of IRE1a in Lipid Metabolismof a number of sterol biosynthesis-related genes such as Fdps,
Sqle, Cyp51, Pmvk, Fdft1, Hsd17b7, Sc4mol, Mvk, and Idi1
was also reduced in both XBP1- and IRE1a-deficient mice,
and hence might contribute to the decreased lipid levels in these
mutant mice.
Among the 237 genes that were suppressed in XBP1-deficient
liver, 112 genes were induced by IRE1a siRNA treatment in
XBP1-deficient mice—these genes represent RIDD substrates
(Figure 3C). Notably, a number of genes involved in lipid metab-
olism in addition to Dgat2, Acacb, and Pcsk9 were identified
as RIDD substrates, likely contributing to the suppression of
plasma lipid levels by activated IRE1a. Acacb and Pcsk9 were
not included in the microarray analysis because of weak signals.
Tunicamycin activates IRE1a and hence would decrease the
expression of RIDD substrates. Indeed, most of the genes that
were suppressed by tunicamycin were induced by IRE1a siRNA
in XBP1-deficient liver (Figure 3A). Among RIDD substrates,
Hsd17b7, Idi1, Mvk, Sc4mol, and Pmvk, which participate in
sterol biosynthesis, were suppressed in IRE1a-deficient mice,
suggesting that XBP1 regulates these genes in both RIDD-
dependent and -independent manners.
Identification of Ces1 and Angptl3 mRNAs
as RIDD Substrates
A notable group of RIDD substrates was the Ces1 gene family.
The mouse genome contains eight highly homologous CES1-
like genes in tandem, generated by gene duplication events
during evolution (Figures S3A and S3B) (Holmes et al., 2010).490 Cell Metabolism 16, 487–499, October 3, 2012 ª2012 Elsevier InCes1 genes encode enzymes that possess TG and choles-
terol-ester hydrolase activities, and have been implicated in
the hydrolysis of neutral lipids stored in lipid droplet and VLDL
formation (Parathath et al., 2011; Quiroga and Lehner, 2011;
Wei et al., 2010). Notably, ablation of Ces3/TGH encoded by
the Ces1d gene decreased plasma TG and cholesterol levels
without causing steatosis (Wei et al., 2010). Ces1c, Ces1d,
Ces1e, Ces1f, and Ces1g mRNA levels were strikingly lower in
XBP1-deficient, but not in IRE1a-deficient, liver compared with
WT controls (Figure 4A). Further, these mRNAs were induced
by IRE1a siRNA in Xbp1LKO liver and suppressed by tunicamycin
treatment in WT mice. Western blot analysis of liver lysates re-
vealed marked reduction of TGH (Ces1d) and Es-X (Ces1g)
proteins in XBP1-deficient liver (Figure 4B). IRE1a-induced
degradation of Ces1 mRNAs may contribute to the hypolipi-
demic phenotype of XBP1-deficient mice.
Interestingly, angiopoietin-like protein 3 (Angptl3) mRNA
was also identified as a RIDD substrate in the microarray
analysis. ANGPTL3 protein is produced and secreted mainly
by liver both in humans and mice, and possesses inhibitory
activity toward lipoprotein lipase and endothelial lipase (Oike
et al., 2005). Accordingly, genetic loss of ANGPTL3 resulted
in decreased plasma TG and cholesterol levels in both species
(Fujimoto et al., 2006; Koishi et al., 2002; Musunuru et al.,
2010; Shimamura et al., 2007). qRT-PCR confirmed that
Angptl3 mRNA levels were markedly lower in XBP1-deficient
liver compared with WT (Figure 4C). Angptl4 and Angptl6
mRNAs that are also abundantly produced in liver were not
altered by XBP1 deficiency (Figure 4C). Consistent with the
reduction of Angptl3 mRNA by XBP1 deficiency, plasma
Angptl3 protein concentration was also markedly decreased
in Xbp1D mice (Figure 4D). Administration of IRE1a siRNA
into Xbp1LKO mice significantly induced hepatic Angptl3
mRNA and plasma Angptl3 protein levels, indicating that hy-
peractivated IRE1a reduces Angptl3 expression in the liver
(Figures 4E and 4F). We used Angptl3 siRNA to reduce
Angptl3 expression in WT mice to levels comparable to what
we observed in Xbp1D mice. This strategy markedly decreased
both plasma TG and cholesterol levels, suggesting that
IRE1a-induced degradation of Angplt3 mRNA contributes
to the hypolipidemia phenotype of XBP1 deficient mice
(Figures S3C–S3F).
To directly demonstrate that Angptl3 mRNA is cleaved by
IRE1a, we performed in vitro cleavage assays using recombinant
IRE1a. Angptl3 mRNA synthesized in vitro was efficiently
cleaved by IRE1a into two smaller fragments (Figure 4G). Anal-
ysis of the mRNA secondary structure predicted the presence
of a hairpin structure in Angptl3 mRNA, which was similar to
the IRE1a cleavage site in XBP1 mRNA (Figure 4H). Mutation
of the potential cleavage site abolished the cleavage of Angptl3
mRNA by IRE1a, demonstrating that IRE1a recognizes the
hairpin structure and cleaves Angptl3 mRNA (Figure 4G). To
further validate the IRE1a cleavage site in Angptl3 mRNA, we
transfected 293T cells with WT or cleavage site mutant Angptl3
expression plasmids together with IRE1a, and measured the
mRNA levels. IRE1a is activated by overexpression in 293T
cells and reduced the expression of WT, but not the mutant
Angptl3 mRNA (Figure 4I), indicating that IRE1a degraded only
the WT Angptl3 mRNA.c.
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Role of IRE1a in Lipid MetabolismAblation of XBP1 Ameliorates Hepatic Steatosis and
Liver Damage in Dietary and Genetic Animal Disease
Models
IRE1a and XBP1 activate hepatic lipid metabolism via transcrip-
tional and posttranscriptional regulation of genes in lipid meta-
bolic pathways. However, the IRE1a/XBP1 signaling pathway
is also considered to have a cytoprotective role against ER
stress, which has been implicated in metabolic abnormalities in
various organs (Cnop et al., 2012; Ron andWalter, 2007). Several
reports have demonstrated that fat accumulation causes ER
stress in liver (Nakatani et al., 2005; Ozcan et al., 2004; Puri
et al., 2008; Sha et al., 2011).We askedwhether XBP1 deficiency
would ameliorate fat accumulation in liver and blood under
metabolic stress conditions, given its lipid-lowering effect, or
would instead heighten ER stress and lipotoxicity, leading
to increased cell death. We investigated the effects of XBP1
deficiency in two dyslipidemic animal models: leptin-deficient
ob/ob mice and mice fed a high-fat diet.
Ablation of Xbp1 in the liver of ob/ob mice was achieved by
generating compound mutant mice (Xbp1LKO;ob/ob) harboring
a homozygous Xbp1 flox allele, Alb-cre transgene, and ob/ob
mutation. Compared with the Xbp1f/f;ob/ob mice littermate
control, Xbp1LKO;ob/ob mice displayed markedly lower hepatic
TG and plasma cholesterol levels (Figure 5A and Figure S4A),
associated with decreased lipogenic gene mRNA levels (Fig-
ure 5B), similar to Xbp1LKO mice. Plasma ALT levels were
comparable between Xbp1f/f;ob/ob and Xbp1LKO;ob/ob mice,
indicating that the ablation of Xbp1 did not augment liver
damage in ob/ob mice (Figure 5A). CHOP, GADD34, Herpud1,
and BiP mRNAs, which are strongly induced under ER stress
conditions by the PERK and ATF6 pathways, were not induced
in Xbp1LKO;ob/ob mice (Figure 5B), suggesting that XBP1 abla-
tion did not induce measurable ER stress in ob/ob mouse liver.
Furthermore, contrary to the notion that fat accumulation
induces ER stress in liver, we failed to detect any measurable
induction of UPR markers such as phospho-IRE1a; phospho-
PERK; phospho-eIF2a; processed nuclear ATF6a and XBP1s
proteins; and BiP, CHOP, and ERdj4 mRNAs in ob/ob mouse
liver (Figures S4B and S4C), suggesting that the causal relation-
ship between fat accumulation and ER stress induction in liver
should be reassessed.
Feeding a high-fat diet increased plasma and hepatic TG in
Xbp1D mice to a level similar to that in WT mice (Figure 5C and
Figure S4D). However, plasma cholesterol levels were lower in
HFD-fed Xbp1Dmice than in WT mice. Interestingly, the plasma
ALT level was significantly lower in Xbp1D compared to WT
mice (Figure 5C), indicating decreased hepatotoxicity in the
absence of XBP1. We did not observe any differences in glucose
tolerance and insulin tolerance tests between WT and Xbp1D
mice under HFD conditions (Figures S4E and S4F).
Ablation of XBP1 in ApoE-Deficient Mice Can
Significantly Decrease Plasma Cholesterol
ApoE-deficient mice display high levels of plasma cholesterol
and are widely used as a model for atherosclerosis (Zadelaar
et al., 2007). To test whether XBP1 ablation could lower
cholesterol levels and reduce atherosclerotic lesion develop-
ment under such extreme conditions, we generated ApoE/;
Xbp1f/f;Mxcre mice that harbored a poly(I:C)-inducible cre re-Cellcombinase transgene. Poly(I:C) administration activated the
Cre and ablated XBP1 to generate ApoE and XBP1 double
knockout (ApoE/;Xbp1D) mice. Inducible XBP1 deletion in
ApoE/ mice significantly decreased plasma TG and choles-
terol levels, although the latter still remained substantially
elevated at >200 mg/dL (Figures 6A and 6B). FPLC analysis of
the lipoprotein profile demonstrated that the cholesterol dis-
tribution was not altered by XBP1 ablation in ApoE/ mice
(Figure 6C). Not surprisingly, despite reductions in plasma
cholesterol and TG levels in ApoE/;Xbp1D compared with
ApoE/ mice, atherosclerotic lesion formation was not sig-
nificantly different between these two groups, as measured by
the oil red O-stained areas in the descending aorta and aortic
arch (Figures 6D and 6E and Figure S5). Thus the 30%–40%
reduction in plasma cholesterol levels achieved by XBP1 abla-
tion, while very significant, was not sufficient to prevent lesion
formation in the setting of ApoE deficiency.
Effect of XBP1 siRNA on Plasma Lipids
In recent years, RNA interference has received considerable
attention as a novel therapeutic strategy, as sequence-specific
siRNA molecules can target virtually any disease-associated
gene with high specificity (Vaishnaw et al., 2010). XBP1 is an
attractive target for RNA therapeutics, given the profound
reduction of plasma TG and cholesterol by XBP1 ablation. We
investigated if the targeted delivery of XBP1 siRNA to the liver
would decrease plasma lipid levels. Intravenous injection of
lipidoid-formulated XBP1 siRNA decreased XBP1 mRNA and
protein levels in the liver in a dose-dependent manner, result-
ing in near-complete suppression of XBP1s protein at doses
>5 mg/kg (Figures 7A and 7B). It is notable that an intermediate
dose of 2.5 mg/kg siRNA had no effect on XBP1s protein level,
despite 50% reduction of XBP1 mRNA, indicating precise
regulation of IRE1a activation to maintain constant XBP1s
protein levels in the liver. Silencing of XBP1s expression was
stably maintained for more than a week after a single injection
of XBP1 siRNA at 7.5 mg/kg (Figure 7C). Similar to the effect
of genetic ablation of XBP1, XBP1 siRNA induced IRE1a hyper-
activation and decreased the expression of genes involved in
lipid metabolism, similar to what we observed in XBP1 knockout
mice (Figures 7D and 7E). XBP1 siRNA transiently decreased
plasma TG and cholesterol levels not only in C57BL/6 mice
(Figures 7F and 7G) but also in apoE-deficient mice (Figures
7H and 7I), indicating that XBP1 siRNA can efficiently reduce
even very elevated plasma lipid levels.
DISCUSSION
We have previously demonstrated that ablation of XBP1 in the
liver resulted in a profound reduction of plasma TG and choles-
terol unaccompanied by hepatic steatosis (Lee et al., 2008).
Here, we demonstrate that IRE1a hyperactivation and the con-
sequent RIDD substantially contribute to the hypolipidemia
phenotype of XBP1-deficient mice. XBP1 deficiency results in
a feedback activation of IRE1a, inducing the degradation of
mRNAs of a cohort of lipid metabolism genes, such as Dgat2,
Acacb, Pcsk9, Angptl3, and Ces1, which regulate TG and
cholesterol metabolism at multiple levels. Dgat2 and Acacb
encode key lipogenic enzymes, Pcsk9 is involved in LDLMetabolism 16, 487–499, October 3, 2012 ª2012 Elsevier Inc. 491
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Figure 4. Identification of Ces1 and Angptl3 mRNAs as RIDD Substrates
(A) Microarray signals for Ces1 genes.
(B) Western blot analysis of liver lysates of WT and Xbp1LKO mice using TGH (Ces1d) antibody which also detects Es-X (Ces1g).
(C) Angptl3, Angptl4, and Angptl6 mRNA levels were measured in the liver of WT and XBP1-deleted male mice. n = 4 per group.
(D) Plasma Angptl3 protein levels in WT and Xbp1D mice measured by ELISA.
(E) Hepatic Angptl3 mRNA levels measured 8 days after siRNA injection of Xbp1LKO mice. n = 3–5 per group.
(F) Plasma Angptl3 protein levels measured 4 or 8 days after siRNA injection to Xbp1LKO mice. n = 3–5 per group.
(G) In vitro-transcribed Angptl3 mRNA was incubated with recombinant IRE1a and then resolved on an agarose gel. Angptl3 mut was generated by changing the
two G residues to C, shown in boldface in (H).
(H) Predicted secondary structure of Angptl3 mRNA with a potential IRE1a cleavage site that is depicted by an arrow.
(I) WT and mutant Angptl3 constructs were transfected into 293T cells together with WT or mutant IRE1a constructs. EGFP plasmid was also included in
the transfection cocktail and served as a normalization control. Angptl3 mRNA levels in the transfected cells were measured by qRT-PCR. Values represent
mean ± SEM. ***p < 0.001.
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Role of IRE1a in Lipid Metabolismclearance, Angptl3 suppresses LPLmediated TG clearance, and
Ces1 possesses TG hydrolyzing activity and is implicated in fatty
acids mobilization from lipid droplets to nascent VLDL. Hence,
suppression of these genes by IRE1a is likely to contribute to
the striking hypolipidemic phenotype mediated by liver-specific
loss of XBP1.
IRE1a regulates hepatic lipid metabolism via two distinct
mechanisms. First, IRE1a promotes the degradation of mRNAsFigure 3. Identification of Direct XBP1 Targets and RIDD Substrates b
(A) Comparison of gene expression profiles between WT and Xbp1D, WT and Ire
Xbp1LKO. Shown are data for 237 genes that were decreased in Xbp1D liver.
(B) mRNA levels of 64 genes that were suppressed in both Xbp1D and Ire1D live
(C) mRNA levels of 112 genes that were induced by IRE1a siRNA in Xbp1LKO liver
metabolism genes are highlighted in red.
Cellencoding lipid metabolism genes such as Dgat2, Acacb, Ces1,
Angptl3, and Pcsk9, which play important roles in de novo
lipogenesis, hydrolysis of cholesterol ester and TG, and lipopro-
tein catabolism. Second, IRE1a activates its downstream
transcription factor XBP1, which can directly activate certain
lipid metabolism genes. Hence, the combined effects of XBP1
deficiency coupled with IRE1a hyperactivation cause a pro-
found reduction of plasma lipids in XBP1-deficient mice.y Microarray Analysis
1D, untreated (NT) and tunicamycin-treated, and siLuc and siIre1 injection to
r in individual liver samples.
. Genes involved in protein folding processes in the ER are shown in blue. Lipid
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Figure 5. Effects of XBP1 Ablation in Dyslipidemic Mouse Models
(A) Metabolic parameters of 8-week-old Xbp1f/f;ob/ob and Xbp1LKO;ob/ob
mice measured after a 4 hr fasting. n = 4–6 female mice per group.
(B) Hepatic mRNA levels were measured by qRT-PCR.
(C) WT and Xbp1D mice were fed a high fat diet for 5 months and then sacri-
ficed to measure metabolic parameters. n = 9–10 male mice per group. Values
represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Role of IRE1a in Lipid MetabolismIRE1a-deficient mice are defective in both XBP1s-mediated
activation of lipogenic genes and IRE1a-mediated mRNA
degradation. Under regular-chow-fed conditions, IRE1a activity
in liver is low, exerting minimal effect on the levels of RIDD sub-
strates, but producing measurable amounts of XBP1s protein,
suggesting that the modest hypolipidemia of IRE1a-deficient
mice is caused mainly by the lack of XBP1s.
In that case, how does XBP1s deficiency cause hypolipidemia
independently of RIDD in IRE1a-deficient mice? We previously
demonstrated that XBP1 directly activated Dgat2 and Acacb
lipogenic genes, which might contribute to the hypolipidemia
observed in the absence of XBP1. However, these genes were
not suppressed in IRE1a-deficient liver, but were induced by
IRE1a siRNA in XBP1-deficient liver, indicating that these genes
are primarily regulated by RIDD. In contrast, microarray analysis
identified various lipid metabolism genes such as Fdps, Sqle,
Cyp51, Pmvk, Fdft1, Hsd17b7, Sc4mol, Mvk, and Idi1 that
were suppressed in both XBP1- and IRE1a-deficient liver, hence
representing direct XBP1 targets. We speculate that XBP1
directly regulates the expression of a subset of lipid metabolism
genes including those listed above, contributing to the hypolipi-
demia phenotype observed in IRE1a-deficient mice. It is also
possible that the alteration of ER protein folding homeostasis494 Cell Metabolism 16, 487–499, October 3, 2012 ª2012 Elsevier Incaused by XBP1 deficiency indirectly affected lipid metabolism.
For example, VLDL assembly occurs in the ER lumen and
involves the folding and lipidation of apoB-100. Although apoB
turnover was not substantially altered in XBP1- or IRE1a-defi-
cient primary hepatocytes (Lee et al., 2008; Zhang et al., 2011),
it is possible that XBP1 deficiency impairs VLDL assembly
and/or secretion in vivo. Supporting this scenario, IRE1a-defi-
cient mice were reported to be more susceptible to tunicamy-
cin-induced hepatic steatosis (Zhang et al., 2011), which is
likely to be caused by the inhibition of hepatic VLDL secretion
(Lee and Glimcher, 2009; Liao and Chan, 2001).
It is notable that XBP1 ablation did not cause any deleterious
effect on the viability of hepatocytes. On the contrary, XBP1
ablation in the liver protected mice from hepatic steatosis and
liver damage caused by prolonged HFD feeding or leptin
deficiency (ob/ob mice). XBP1 ablation in the liver of ob/ob
mice markedly ameliorated hepatic steatosis, paralleled by the
suppression of the expression of lipogenic genes. Feeding
a high-fat diet caused liver damage in WT mice, which was
ameliorated in XBP1-deficient mice. Oxidative stress has been
implicated in HFD-induced liver cell death (Anstee and Goldin,
2006). It remains to be determined if XBP1 deficiency altered
the generation of ROS, or the sensitivity of hepatocytes to oxida-
tive damage.
The ER is a crucial subcellular compartment for many physi-
ological functions of the liver, including lipogenesis, lipoprotein
production, protein secretion, and detoxification of xenobiotics.
One might speculate that an increased burden of lipids,
proteins, and xenobiotics on the ER would impair ER function,
evoking a stress response. Supporting this hypothesis, several
papers have reported UPR activation in various liver diseases
as a marker of ER stress (Hotamisligil, 2008; Ozcan et al.,
2004; Puri et al., 2008). Notably, it has been shown that TG
accumulation in the liver in obesity causes ER stress, and the
disruption of the UPR exacerbates the consequences of meta-
bolic abnormalities such as insulin resistance (Hotamisligil,
2008; Ozcan et al., 2004; Park et al., 2010; Winnay et al.,
2010; Zhou et al., 2011). In stark contrast, we failed to detect
any measurable UPR activation (IRE1a and PERK phosphoryla-
tion, ATF6a processing, CHOP and BiP mRNA induction) in the
liver of ob/ob mice, arguing against the involvement of the UPR
in the metabolic abnormalities in this animal model. Our data
are consistent with a recent report that demonstrated increased
hepatic insulin sensitivity in XBP1-deficient mice, which was
associated with decreased TG accumulation in the liver and
plasma (Jurczak et al., 2012). It is important to note that our
data do not disprove the involvement of ER dysfunction in
metabolic stress, given that we actually did not measure ‘‘ER
stress,’’ defined as the increase of misfolded or unfolded
protein species in the ER, in ob/ob mice, which is currently
not feasible. Although UPR activation has been used as a
marker of ER stress, the immediate upstream stimuli activating
UPR in normal and diseased liver are not defined. It is possible
that metabolic stresses compromise the ER function without
UPR activation.
XBP1-deficient liver displays a qualitatively and quantita-
tively normal lipid profile with no hepatic steatosis. This is
in contrast to ApoB siRNA treated or Mttp mutant mice
where lipid accumulates in the liver due to impaired VLDLc.
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Figure 6. Ablation of XBP1 in apoE Knockout Mice Reduces Plasma Lipids
(A and B) (A) Apoe/;Xbp1f/f and Apoe/;Xbp1f/f;Mx-cre mice were injected with poly(I:C) on day 0, day 4, week 12, and week 20. Bloods were drawn at fed
state to measure plasma TG and (B) cholesterol levels. n = 8–9 per group. Values represent mean ± SEM. **p < 0.01, ***p < 0.001 compared with the control group
(Apoe/;Xbp1f/f mice).
(C) Plasma collected at weeks 8 and 17 were pooled and subjected to FPLC analysis.
(D and E) Descending aorta and aortic arch were stained with oil red O (ORO), and ORO-positive areas were quantified.
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Role of IRE1a in Lipid Metabolismassembly/secretion (Raabe et al., 1999; Tadin-Strapps et al.,
2011). Dramatic reduction of plasma lipids coupled with pres-
ervation of the normal hepatic lipid profile in XBP1-deficient
mice suggests that XBP1 is a promising target for drug devel-
opment to treat dyslipidemias. We demonstrated that XBP1
siRNA lowered plasma lipid levels both in WT C57BL/6 and
in apoE-deficient mice, providing proof of principle for target-
ing XBP1 to treat dyslipidemias. Alternatively, small molecule
compounds modulating IRE1a could be useful to lower plasma
lipid levels. Since genetic ablation of IRE1a in the liver
decreased plasma lipid levels, compounds that inhibit IRE1a
activity are expected to have similar lipid-lowering effects.
IRE1a activators could also decrease plasma lipid levels by
promoting the degradation of mRNAs of lipid metabolism
genes. IRE1a activation would also induce XBP1s, which can
promote lipogenesis. The effects of IRE1a activation coupledCellwith XBP1s induction on lipid homeostasis remain to be further
investigated.
EXPERIMENTAL PROCEDURES
Mice
Xbp1flox mice were crossed with interferon-inducible B6.Cg-Tg(Mx1-cre)
1Cgn/J or C57BL/6-Tg(Alb-cre)21Mgn/J strains of mice (Jackson Laboratory)
that produce cre recombinase under the control of the mouse albumin
promoter and efficiently delete the floxed gene in the liver as previously
described (Lee et al., 2008). Ern1flox mice have been previously described
(Iwawaki et al., 2009) and crossed with Mx1-cre mice to inducibly delete
IRE1a in the liver. Mice were housed in a specific pathogen-free facility at the
Harvard School of Public Health and had free access to water and standard
chow diet (PicoLab Rodent diet 20, #5058, Lab diet), which consisted of
12% fat, 23.5% protein, and 64.5% carbohydrate, or a high-fat diet (45% fat,
18.6%protein, and 36.4%carbohydrate; TestDiet, #58G8).Mice heterozygous
for a leptin mutation (B6.V-Lepob/J) were obtained from The JacksonMetabolism 16, 487–499, October 3, 2012 ª2012 Elsevier Inc. 495
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Figure 7. Silencing of XBP1 mRNA In Vivo
(A) Female C57BL/6 mice were i.v. injected with PBS, luciferase siRNA (5mg/kg), or varying doses of XBP1 siRNA. Mice were sacrificed 48 hr later. Hepatic XBP1
mRNA levels were measured by qRT-PCR. n = 4 mice per group. Values represent mean ± SEM. ***p < 0.001 compared with the control groups (PBS and
luciferase siRNA groups).
(B) Western blot to measure XBP1s protein levels in pooled nuclear extracts. Asterisk indicates nonspecific band.
(C) Mice were injected with siRNAs at 7.5 mg/kg and sacrificed after indicated days to measure hepatic XBP1s protein levels by western blot. SP1 serves as
a loading control. n = 3–4 mice per group.
(D) qRT-PCR analysis of hepatic gene expression. n = 3 per group. *p < 0.05.
(E) Western blot analysis of IRE1a in liver lysates. The panel shows IRE1a phosphorylation measured by Phos-Tag western blot.
(F—I) (F and G) Male C57BL/6, or (H and I) Apoe/ mice were i.v. injected with siRNAs (7.5 mg/kg) and bled to measure plasma lipid levels. n = 5–8 per group.
Values represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control group (siLuc).
Cell Metabolism
Role of IRE1a in Lipid MetabolismLaboratory and intercrossed to produce homozygous ob/obmice, or bred onto
Xbp1LKO mice to generate Xbp1LKO;ob/ob mice. Xbp1f/f;Mx1-cre mice were
crossed to ApoE/ mice (Jackson Laboratory, B6.129P2-Apoetm1Unc/J) and496 Cell Metabolism 16, 487–499, October 3, 2012 ª2012 Elsevier Ininjected with poly(I:C) to generate XBP1 and ApoE double deficient mice.
Animal studies and experiments were approved and carried out according to
the guidelines of the Animal Care and Use Committee of Harvard University.c.
Cell Metabolism
Role of IRE1a in Lipid MetabolismIn Vivo siRNA Delivery
XBP1 siRNA (sense, 50-CACCCUGAAUUCAUUGUCU-30; antisense, 50-AGA
CAAUGAAUUCAGGGUG-30) was formulated with lipidoid 98N12-5 as
described previously (Frank-Kamenetsky et al., 2008). XBP1 and luciferase
siRNAs (Frank-Kamenetsky et al., 2008) were diluted in PBS and injected
into mice via the tail vein at 5 ml/g body weight. IRE1a (sense, 50-AUGCCGA
AGUUCAGAUGGADTSDT-30; antisense, 50-UCCAUCUGAACUUCGGCAUD
TSDT-30) and control luciferase siRNAs formulated with lipidoid C12-200
were injected via tail vein as described previously (Hur et al., 2012; Love
et al., 2010).
Blood Chemistry and Measurement of Liver TG Contents
Plasma TG and cholesterol levels were measured by using commercial
Triglyceride Reagent (Sigma) and the Amplex Red Cholesterol Assay Kit
(Invitrogen), respectively, following the manufacturer’s instructions. Plasma
Angplt3 levels were measured using a commercial ELISA kit (R&D Systems).
Fast performance liquid chromatography (FPLC) analysis of plasma samples
was performed as described previously (Lee et al., 2011). Serum alanine
aminotransferase (ALT) activity was measured using a commercial reagent
(Bioquant). Lipids were extracted from liver tissue by Folch’s method and
subjected to TG assay.
RNA Isolation, qRT-PCR, and Microarray Analysis
Total RNA was extracted from liver using Qiazol lysis reagent (QIAGEN)
and reverse transcribed into cDNA using High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). qRT-PCR was performed as described
previously (Lee et al., 2008). RNA samples from individual mice were further
purified using RNeasy MinElute Cleanup Kit (QIAGEN), and then used for
the production of biotin-labeled cRNA followed by hybridization with HT
MG-430 PM Array Plate (Affymetrix). Two-hundred thirty-seven XBP1-depen-
dent genes were identified by comparing WT and Xbp1D liver samples with
minimum fold-change criterion of 1.6 and p % 0.005. Relaxed criteria (p %
0.05) were used for the comparison between WT and Ire1D, untreated and
tunicamycin treated, and luciferase and IRE1a siRNA.
Cell Culture and Transfection
HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine
serum. Transient transfection was performed using Lipofectamine 2000
(Invitrogen), as described previously (Lee et al., 2011).
Western Blot
Liver tissues were homogenized in RIPA buffer (50 mM Tris-Cl [pH 8.0],
150mMNaCl, 1%NP40, 0.5% deoxycholate, 0.1% SDS, 50mMNaF) supple-
mented with protease inhibitor tablet (Roche). Homogenates were centrifuged
at 12,000 g for 10 min at 4C, and the supernatants were collected. Liver
nuclear extracts were prepared as described previously (Lee et al., 2008). Liver
lysates were used for western blotting as described previously (Hur et al.,
2012).
In Vitro IRE1a-Mediated mRNA Cleavage Assays
Cleavage of in vitro-transcribed Angptl3 mRNA by recombinant IRE1a was
tested as described previously (Lee et al., 2011). Briefly, pCMV-SPORT6-
Angptl3 (BC019491, Open Biosystems) plasmid was linearized by BglII diges-
tion and incubated with SP6 polymerase to produce Angptl3 RNA. Angptl3mut
construct was generated using QuikChange Site-Directed Mutagenesis Kit
(Stratagene), based on the predicted mRNA secondary structure (http://rna.
tbi.univie.ac.at/cgi-bin/RNAfold.cgi). In vitro-transcribed RNAs were incu-
bated with the recombinant protein including the cytosolic domain of human
IRE1a, resolved on a 1.2% denaturing agarose gel, and visualized by ethidium
bromide staining.
Quantification of Atherosclerosis Lesions
The aortas were harvested and fixed overnight in 10% buffered formalin
solution. Atherosclerotic lesions were analyzed in the aortic arch, and de-
scending aorta by oil red O staining as previously described (Gotsman et al.,
2007; Gotsman et al., 2006).CellStatistical Analysis
Values represent mean ± SEM. Statistical significance of differences between
groups was determined by Student’s t tests. P values less than 0.05 were
considered to be significant.
ACCESSION NUMBERS
Microarray data have been deposited in the Gene Expression Omnibus (GEO)
under accession code GSE40515.
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